[hat-tip: http://www.flutrackers.com/forum/showthread.php?t=207053]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Determination and Declaration Regarding Emergency Use of in vitro
Diagnostics for Detection of Middle East respiratory syndrome
coronavirus (MERS-CoV)
AGENCY:
Department of Health and Human Services, Office of the Secretary
ACTION:Notice.
SUMMARY:
The Secretary of Health and Human Services (HHS) is issuing this notice
pursuant to section 564 of the Federal Food, Drug, andCosmetic
(FD&C) Act, 21 U.S.C. § 360bbb-3. On May 29, 2013, the Secretary
determined that
there is a significant potential for a public health emergency that has a
significant potential to affect national security or the health and
security of United States citizens living abroad and that involves
Middle East respiratory syndrome coronavirus (MERS-CoV).
On the basis of this determination, she also declared that circumstances
exist justifying the authorization of emergency use of in vitro
diagnostics for detection of Middle East respiratory syndrome
coronavirus (MERS-CoV) pursuant to section 564 of the FD&C Act,
subject to the terms of any authorization issued under that section.
2
DATES:
The determination and declaration are effective May 29, 2013.
FOR FURTHER INFORMATION CONTACT:
Nicole Lurie, M.D., MSPH, Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and
Human Services, 200 Independence Avenue, SW., Washington, DC 20201, Telephone (202) 205-2882 (this is not a toll free number).
SUPPLEMENTARY INFORMATION:
I. Background
Under Section 564 of the FD&C Act, the Commissioner of the Food and
Drug Administration (FDA), acting under delegated authority from the
Secretary of HHS, may issue an Emergency Use Authorization (EUA)
authorizing 1) the emergency use of an unapproved drug, an unapproved or
uncleared device, or an unlicensed biological product; or 2) an
unapproved use of an approved drug, approved or cleared device, or
licensed biological product. Before an EUA may be issued, the Secretary
of HHS must declare that circumstances exist justifying the
authorization based on one of four determinations: 1) a determination by
the Secretary of Homeland Security that there is a domestic emergency,
or a significant potential for a domestic emergency, involving a
heightened risk of attack with a, chemical, biological, radiological, or
nuclear ("CBRN") agent or agents; 2) the identification of a material
threat by the Secretary of Homeland Security pursuant to section
319F-2of the Public Health Service (PHS) Act 1
sufficient to affect national security or the health and security of
United States citizens living abroad; 3) a determination by the
Secretary of Defense that there is a military emergency, or a
significant potential for a military emergency, involving a heightened
risk to United States military forces of attack with a CBRN agent or
agents; or 4) a determination by the Secretary that there is a public
health emergency, or a significant potential for a public health
emergency, that affects, or has a significant potential to affect,
national security or the health and security of United States citizens
living abroad, and that involves a CBRN agent or agents, or a disease or
condition that may be attributable to such agent or agents.2
Based on any of these four determinations, the Secretary of HHS may then
declare that circumstances exist that justify the EUA, at which point
the FDA Commissioner may issue an EUA if the criteria for issuance of an
authorization under section 564 of the FD&C Act are met.
The Centers for Disease Control and Prevention (CDC), HHS, requested
that the FDA, HHS,issue an EUA for in vitro diagnostics for detection of
Middle East respiratory syndrome coronavirus (MERS-CoV) to allow the
Department to take preparedness measures based on information currently
available about the Middle East respiratory syndrome coronavirus
(MERS-CoV). The determination of a significant potential for a public
health emergency, and the declaration that circumstances exist
justifying emergency use of in vitro diagnostics for detection of Middle
East respiratory syndrome coronavirus (MERS-CoV) by the Secretary of
HHS, as described below, enable the FDA Commissioner to issue an EUA for
certain in vitro diagnostics for emergency use under section 564 of the
FD&C Act.
II. Determination by the Secretary of Health and Human Services
On May 29, 2013, pursuant to section 564of the FD
&C Act, I determined that there is a significant potential for a
public health emergency that has a significant potential to affect
national security or the health and security of United States citizens
living abroad and that involves Middle East respiratory syndrome
coronavirus (MERS-CoV).
III. Declaration of the Secretary of Health and Human Services
Also on May 29, 2013, on the basis of my determination of a significant
potential for a public health emergency that has a significant potential
to affect national security or the health and security of United States
citizens living abroad and that involves Middle East respiratory
syndrome coronavirus (MERS-CoV), I declared that circumstances exist
justifying the authorization of emergency use of in vitro diagnostics
for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)
pursuant to section 564 of the FD&C Act, subject to the terms of
any authorization issued under that section.
Notice of the EUAs issued by the FDA Commissioner pursuant to this
determination and declaration will be provided promptly in the Federal
Register as required under section 564 of the FD&C Act.
1 42 U.S.C. § 247d-6b
2 As amended by the Pandemic and All-Hazards Preparedness
Reauthorization Act, Pub.L. No. 113-5,the Secretary may make
determination of a public health emergency, or a significant potential
for a public health emergency, under section 564 of the FD&C Act.
The Secretary is no longer required to make a determination of a public
health
emergency in accordance with section 319 of the PHS Act, 42 U.S.C. §
247d to support a determination or declaration made under section 564 of
the FD&C Act.
May 29, 2013
Dated
Kathleen Sebelius
[FR Doc. 2013-13333 Filed 06/04/2013 at8:45 am; Publication Date: 06/05/2013]
__________________
http://www.ofr.gov/%28S%28w2qmxmwvomli54azuaimwev5%29%29/OFRUpload/OFRData/2013-13333_PI.pdf
1 comment:
Interesting story. Will make me think twice next time I visit the doctor!
-Jon @ human services software
Post a Comment